A position paper: Based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer’s disease cholesterol-lowering treatment trial (ADCLT)

By Sparks D.   Lopez Jean   Connor Don   Sabbagh Marwan   Seward Jim   Browne Patrick  

Journal of Molecular Neuroscience, Vol. 20, Iss. 3, 2003-08 ,pp. : 407-410

Humana Press, Inc

Access to resources Recommend Favorite

Cholesterol Metabolism and Brain Amyloidosis: Evidence for a Role of Copper in the Clearance of A &bgr; Through the Liver

By  

Current Alzheimer Research, Vol. 4, Iss. 2, 2007-04 ,pp. : 165-169

Bentham Science Publishers

Access to resources Recommend Favorite

Atorvastatin Therapy Lowers Circulating Cholesterol but not Free Radical Activity in Advance of Identifiable Clinical Benefit in the Treatment of Mild-to-Moderate AD

By  

Current Alzheimer Research, Vol. 2, Iss. 3, 2005-07 ,pp. : 343-353

Bentham Science Publishers

Access to resources Recommend Favorite

Cholesterol lowering for the prevention of stroke

By  

PRACTICAL NEUROLOGY, Vol. 3, Iss. 4, 2003-08 ,pp. : 224-233

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessing motor and cognitive regulation in AD, MCI, and controls using the Behavioral Dyscontrol Scale

By Belanger Heather G.  

Archives of Clinical Neuropsychology, Vol. 20, Iss. 2, 2005-03 ,pp. : 183-189

Oxford University Press

Access to resources Recommend Favorite